Biologics for pediatric psoriasis: A systematic review and meta‐analysis

Abstract Background Biologics represent a promising treatment for children with moderate‐to‐severe psoriasis. Randomized control trials (RCTs) have been published evaluating different biologics in children with psoriasis, but no summative review exists. Objective To summarize data from existing RCTs to assess the efficacy and safety of biologics in the management of pediatric psoriasis. Methods A systematic review and meta‐analysis of RCTs was performed from Medline, Embase, PubMed, the Cochrane Central Register of Controlled Trials, and the American College of Physicians Journal Club from inception to November 2020. Random‐effects models were used to estimate the pooled effect size. Results Five RCTs assessing adalimumab, etanercept, ixekizumab, secukinumab, and ustekinumab were included (768 patients). The odds ratio of achieving a 75% improvement in Psoriasis Area and Severity index score was 12.37 (95% CI: 6.23‐24.55) at initial follow‐up, defined as 12‐16 weeks of treatment. The odds ratio of any adverse event was 0.95 (95% CI: 0.51‐1.80) at initial follow‐up, in patients treated with biologics when compared to placebo or a non‐biologic agent. Limitations of this study include heterogeneity in both the study design and the biologics investigated between the RCTs included in the meta‐analysis. Conclusion Biologic therapy for pediatric patients with moderate‐to‐severe psoriasis has high efficacy and a favorable side effect profile.